BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32176735)

  • 1. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
    Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
    Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3A is a prominent cytidine deaminase in breast cancer.
    Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
    PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
    Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
    Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
    Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
    Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
    Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
    Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
    Udquim KI; Zettelmeyer C; Banday AR; Lin SH; Prokunina-Olsson L
    Carcinogenesis; 2020 Aug; 41(8):1030-1037. PubMed ID: 31930332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
    Cescon DW; Haibe-Kains B; Mak TW
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
    Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
    PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activation.
    Pan JW; Zabidi MMA; Chong BK; Meng MY; Ng PS; Hasan SN; Sandey B; Bahnu S; Rajadurai P; Yip CH; Rueda OM; Caldas C; Chin SF; Teo SH
    Int J Cancer; 2021 May; 148(10):2489-2501. PubMed ID: 33423300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratinocyte differentiation induces APOBEC3A, 3B, and mitochondrial DNA hypermutation.
    Wakae K; Nishiyama T; Kondo S; Izuka T; Que L; Chen C; Kase K; Kitamura K; Mohiuddin M; Wang Z; Ahasan MM; Nakamura M; Fujiwara H; Yoshizaki T; Hosomochi K; Tajima A; Nakahara T; Kiyono T; Muramatsu M
    Sci Rep; 2018 Jun; 8(1):9745. PubMed ID: 29950685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
    Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
    BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells.
    Wang Y; Li X; Song S; Sun Y; Zhang J; Yu C; Chen W
    Virol J; 2017 Nov; 14(1):211. PubMed ID: 29100527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC3A/B deletion polymorphism and cancer risk.
    Gansmo LB; Romundstad P; Hveem K; Vatten L; Nik-Zainal S; Lønning PE; Knappskog S
    Carcinogenesis; 2018 Feb; 39(2):118-124. PubMed ID: 29140415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
    Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
    Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
    Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
    Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
    Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme.
    Caval V; Bouzidi MS; Suspène R; Laude H; Dumargne MC; Bashamboo A; Krey T; Vartanian JP; Wain-Hobson S
    Nucleic Acids Res; 2015 Oct; 43(19):9340-9. PubMed ID: 26384561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.